Amgen, CVS Health Corp sales and marketing update

CVS has selected Repatha evolocumab from Amgen as its exclusive PCSK9 inhibitor in exchange for undisclosed discounts on the lipid-lowering drug.The PBM said its pharmacy and therapeutics (P&T) committee determined that Repatha and Praluent alirocumab, a competing PCSK9 inhibitor, were therapeutically equivalent.

Amgen said the CVS deal is a value-based contract that links the net price of the human mAb against PCSK9 to expected LDL cholesterol reductions. Amgen declined to disclose additional details, and CVS did not respond to inquiries in time for publication. ...